Bone Biologics (OTC:BBLG) Stock Rating Reaffirmed by EF Hutton Acquisition Co. I

Bone Biologics (OTC:BBLG – Get Rating)‘s stock had its “buy” rating restated by equities researchers at EF Hutton Acquisition Co. I in a research note issued to investors on Thursday, Benzinga reports. They presently have a $2.25 price objective on the stock. Bone Biologics Price Performance OTC BBLG traded down $0.01 on Thursday, hitting $0.24. […]

Related Keywords

,Bone Biologics Corporation ,Ef Hutton Acquisition Co ,Bone Biologics Co ,Bone Biologics Company Profile ,Bone Biologics ,Get Rating ,Street Group ,Biologics Corporation ,Bone Biologics Daily ,Otc Bblg ,Bblg ,Medical ,Reiterated Rating ,Ef Hutton Acquisition Co I ,